A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension

NCT01943721 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2014-12-17

No results posted yet for this study

Summary

The objective of this Phase 1 study is to evaluate the VISION5 Product's safety and efficacy.

Conditions

Interventions

DRUG

VISION5 Product

Sponsors & Collaborators

  • ForSight Vision5, Inc.

    lead INDUSTRY

Principal Investigators

  • Anne Rubin · ForSight VISION5

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • Latvia

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01943721 on ClinicalTrials.gov